Skip to main content
SpringerLink
Log in
Book cover

Adjuvant Therapy of Breast Cancer IV pp 257–266Cite as

Long-Term Toxicity of Tamoxifen

  • Conference paper

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 127))

Abstract

Since tamoxifen was introduced as a treatment for breast cancer in the early 1970s several tens of thousands of patients worldwide have been treated with the drug. The introduction of long-term tamoxifen as an adjunct to primary surgery, particularly in patients with low-risk tumors, means that there will be a growing number of long-term survivors who have been exposed to the drug for several years. The absolute benefit with adjuvant treatment appears to be relatively small - although potentially clinically wortwhile - in low-risk subgroups. In this setting even relatively infrequent adverse side effects could potentially offset the treatment benefit. This may also apply to chemopreventive treatment in previously healthy women aimed at decreasing their risk of developing breast cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fisher B, Costantino J, Redmond C et al. (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–484

    Article  PubMed  CAS  Google Scholar 

  2. Fornander T, Rutqvist LE, Wilking N, Carlström K, van Schoultz B (1992) Estrogenic effecs of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer (in press)

    Google Scholar 

  3. Rössner S, Wallgren A (1984) Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52:339–346

    Article  PubMed  Google Scholar 

  4. Fornander T, Rutqvist LE, Sjöberg HE, Blomqvist L, Mattsson A, Glas U (1990) Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 8:1019–1024

    PubMed  CAS  Google Scholar 

  5. Jackson IM, Litherland S, Wakeling AE (1991) Tamoxifen and other antiestrogens. In: Powles TJ, Smith IE (eds) Medical management of breast cancer Cambridge University Press, Cambridge, pp 51–59

    Google Scholar 

  6. Hendrick A, Subramanian VP (1980) Tamoxifen and thrombembolism JAMA 243:514–515

    Article  PubMed  CAS  Google Scholar 

  7. Lipton A, Harvey HA, Hamilton RW (1984) Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887–889

    PubMed  CAS  Google Scholar 

  8. Nevasaari K, Heikkinen M, Taskinen PJ (1978) Tamoxifen and thrombosis. Lance 2:946–947

    Article  CAS  Google Scholar 

  9. Enck RE, Rios CN (1984) Tamoxifen treatment of metastatic breast cancer and antithrombin-III levels. Cancer 53:2607–2609

    Article  PubMed  CAS  Google Scholar 

  10. Rieche K (1986) Die Beeinflussung des funktioneilen Antithrombin III im plasma durch Tamoxifen und Aminoglutethemid. Krebsmedizin 7:60–63

    Google Scholar 

  11. Jordan VC, Fritz NF, Tormey DC (1987) Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 47:4517–4519

    PubMed  CAS  Google Scholar 

  12. Auger MJ, Mackie MJ (1988) Effects of tamoxifen on blood coagulation. Cancer 61:1316–1319

    Article  PubMed  CAS  Google Scholar 

  13. Saphnerr T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9: 286–294

    Google Scholar 

  14. Barrett-Connor E, Bush TL (1989) Estrogen replacement therapy and coronary heart disease. Cardiovasc Clin 19:159–172

    PubMed  CAS  Google Scholar 

  15. Love RR, Newcomb PA, Wiebe DA et al. (1990) Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327–1332

    Article  PubMed  CAS  Google Scholar 

  16. Breast Cancer Trials Comittee, Scottish Cancer Trials Office (1987) Adjuvant tamoxifen in the mangement of operable breast cancer: the Scottish trial. Lancet 2:171–175

    Google Scholar 

  17. Rutqvist LE, Cedermark B, Glas U et al. (1992) Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer. Acta Oncol (in press)

    Google Scholar 

  18. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1–15, 71–85

    Google Scholar 

  19. Boccardo F, Bruzzi P, Rubagotti A, Nicolo G, Rosso R (1981) Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38:281–285

    Article  PubMed  CAS  Google Scholar 

  20. De Muylder X, Neven P, de Somer M et al. (1991) Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36:127–130

    Article  PubMed  Google Scholar 

  21. Satyaswaroop PG, Zaino RJ, Marbel R (1984) Estrogen-like effecs of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44:4006–4010

    PubMed  CAS  Google Scholar 

  22. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfverswärd C, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117–120

    Article  PubMed  CAS  Google Scholar 

  23. Andersson M, Storm HH, Mouridsen HT (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83:1013–1017

    Article  PubMed  CAS  Google Scholar 

  24. Rydén S, Fernö M, Möller T et al. (1992) Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Trial. Acta Oncol (in press)

    Google Scholar 

  25. Fentiman IS, Powles TJ (1987) Tamoxifen and benign breast problems. Lancet 2:1070–1072

    Article  PubMed  CAS  Google Scholar 

  26. Boccardo F, Rubagotti A, Bruzzi P et al. (1989) Tamoxifen vs chemotherapy vs chemotherapy plus tamoxifen in stage II ER+ breast cancer patients. Preliminary results of the GROCTA trials (Abstr). Proceedings of the 5th European Conference on Clinical Oncology (ECCO-5): Federation of European Cancer Societies, London

    Google Scholar 

  27. Powles TJ, Hardy JR, Ashley SE et al. (1989) A pilot trial to evaluate the acute toxicity and feasability of tamoxifen for prevention of breast cancer. Br J Cancer 60:126–131

    Article  PubMed  CAS  Google Scholar 

  28. Weiss NS, Ure CL, Ballard JH et al. (1980) Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195–1198

    Article  PubMed  CAS  Google Scholar 

  29. Love RR, Mazess RB, Tormey DC et al. (1988) Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:297–301

    Article  PubMed  CAS  Google Scholar 

  30. Ashford AR, Donev I, Tiwari RP, Garret TJ (1988) Reversible ocular toxicity related to tamoxifen therapy. Cancer 61:33–35

    Article  PubMed  CAS  Google Scholar 

  31. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM (1981) Tamoxifen retinopathy: a clinicopathologic report. Ophtalmology 8:89–93

    Google Scholar 

  32. Griffiths MF (1987) Tamoxifen retinopathy at low dosage. Am J Ophtalmol 104:185–186

    CAS  Google Scholar 

  33. Vinding T, Nielsen NV (1983) Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophtalmol (Lopenh) 61:45–50

    Article  CAS  Google Scholar 

  34. Gottardis MM, Robinson SP, Jordan VC (1988) Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30:311–314

    Article  PubMed  CAS  Google Scholar 

  35. Osborne CK, Coronado E, Allred DC et al. (1991) Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477–1482

    Article  PubMed  CAS  Google Scholar 

  36. Abram WP, Baum M, Berstock DA et al. (1988) Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Preliminary analysis by the CRC Adjuvant Breast Trial Working Party. Br J Cancer 57:604–607

    Article  Google Scholar 

  37. Rutqvist LE, Cedermark B, Glas U et al. (1991) Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1299–1306

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncologic Centre, Karolinska Hospital, 104 01, Stockholm, Sweden

    L. E. Rutqvist

Authors
  1. L. E. Rutqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine C, Kantonsspital, CH-9007, St. Gallen, Switzerland

    Hans-Jörg Senn  & Beat Thürlimann  & 

  2. Division of Biostatistics, Dana Farber Cancer Institute, 44, Binney Street, Boston, MA, 02115, USA

    Richard D. Gelber Ph.D.

  3. Ospedale Civico, CH-6900, Lugano, Switzerland

    Aron Goldhirsch

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Rutqvist, L.E. (1993). Long-Term Toxicity of Tamoxifen. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer IV. Recent Results in Cancer Research, vol 127. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84745-5_34

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84745-5_34

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-84747-9

  • Online ISBN: 978-3-642-84745-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation